Chronic Kidney Disease

October 30, 2020

For kidney transplant patients with gout, the use of anti-inflammatory drugs and urate-lowering therapies typically used to prevent flares and slow the progression disease, are associated with the risk of adverse events. In this interview, Dr. Abdul Abdellatif describes a clinical trial that shows pegloticase may be suitable for transplant patients with gout.

October 29, 2020

In today's episode of the Rheumatology Network podcast Overdrive, we talk with Dr. Bradley Marder, medical director of nephrology for Horizon Therapeutics. Gout, he says, is not only a rheumatic disease that affects peripheral joints, it’s a disease that's systemic in nature and progressive. As a nephrologist, he sees gout as kidney disease. In today's episode of Overdrive, he explains why.

October 29, 2020

Anti-inflammatory and immunosuppressive agents are the two primary classes of drugs used to treat lupus nephritis. Now, a new study shows that the addition of the monoclonal antibody belimumab to standard therapy may make a meaningful difference in this hard-to-treat patient population.

October 29, 2020

Although mortality rates for kidney transplant recipients with COVID-19 are known to be high, end stage kidney disease patients with COVID-19 appear to have a higher risk of mortality than patients with new kidneys.

October 28, 2020

A possible new treatment for advanced lupus nephritis passes a phase two trial, according to a study presented at Kidney Week, the annual meeting of the American Society for Nephrology. The treatment, a CD20 antagonist called obinutuzumab, led to improvements in 41 percent of patients with lupus nephritis—a condition that affects one in 60 people with systemic lupus.

October 27, 2020

From COVID-19 presentations to emerging new therapies for chronic kidney disease, Dr. Bradley Marder, medical director of nephrology with Horizon Therapeutics, offers his take on the most memorable moments from the American Society for Nephrology/Kidney Week annual meeting which wrapped this week.

October 23, 2020

The gout treatment allopurinol doesn't appear to slow the progression of chronic kidney disease in patients with moderate to severe loss of kidney function, shows a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

October 23, 2020

Treatments for lupus nephritis can cost patients over $50,000 a year, according to a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

October 02, 2020

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

December 19, 2018

Canadian researchers looked at the safety of short-term use in patients with hypertension, heart failure, or chronic kidney disease.